1213234-94-6

Basic information

• Product Name: ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazol-5-yl}-2H-tetrazol-2-yl)acetate
• Synonyms: ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazol-5-yl}-2H-tetrazol-2-yl)acetate
• CAS NO: 1213234-94-6
• Molecular Weight: 499.768
• Mol File: 1213234-94-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazol-5-yl}-2H-tetrazol-2-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazol-5-yl}-2H-tetrazol-2-yl)acetate(1213234-94-6)
• EPA Substance Registry System: ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazol-5-yl}-2H-tetrazol-2-yl)acetate(1213234-94-6)

Safety Data

• Hazardous Substances Data: 1213234-94-6(Hazardous Substances Data)

Upstream product

• 1213234-93-5 C₁₃H₇Cl₃N₈S 
• 105-36-2 ethyl bromoacetate 
• 1213235-21-2 C₁₀H₁₃NO₂SSi 
• 1213234-92-4 2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazole-5-carbonitrile 
• 1213234-91-3 2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazole-5-carboxamide 
• 1213234-90-2 Methyl 2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazole-5-carboxylate 
• 1213234-89-9 methyl 2-ethynyl-1,3-thiazole-5-carboxylate 
• 1213234-83-3 3,4,5-trichlorobenzyl azide 
• 74878-32-3 4-amino-3,5-dichlorobenzyl alcohol 
• 7520-67-4 3,4,5-trichloro-benzyl alcohol 
• 56961-25-2 4-amino-3,5-dichlorobenzoic acid 
• 1213234-93-5 5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazol-5-yl}-1H-tetrazole 

Downstream Products

• 1213234-71-9 (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1,3-thiazol-5-yl}-2H-tetrazolyl)acetic acid 

Relevant articles and documents

Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors

It has been demonstrated that once-a-day dosing of systemically-distributed SCD inhibitors leads to adverse events in eye and skin. Herein, we describe our efforts to convert a novel class of systemically-distributed potent triazole-based uHTS hits into liver-targeted SCD inhibitors as a means to circumvent chronic toxicity.